Post-PCI corrected TIMI Frame Count predicts left ventricular global longitudinal strain at 90 days post-STEMI in thrombolysis-treated patients: A pre-specified analysis of the MIRTOS study.

Ticagrelor has been established as the P2Y In this pre-specified analysis of the MIRTOS trial, the degree of change in left ventricular ejection fraction (ΔLVEF) and left ventricular longitudinal strain (ΔLV-GLS) from baseline to 90 days post-randomization in all patients who underwent conventional and speckle-tracking echocardiography at both timepoints was compared between the ticagrelor and clopidogrel groups. In addition, speckle-tracking echocardiographic measurements were evaluated for any correlations to post-PCI CTFC. No statistically significant differences were detected between the ticagrelor and clopidogrel groups for ΔLVEF (+3.61 ± 5.08 % versus +2.21 ± 4.78 %; P = 0.18) and ΔLV-GLS (-1.53 ± 2.7 % versus -1.21 ± 3.05 %; P = 0.73). A strong negative correlation was found between post-PCI CTFC and the absolute value of LV-GLS at 90 days post-randomization (r = -0.33, P = 0.014). Our work suggests that both P2Y12-inhibitors are accompanied with a similar degree of myocardial recovery in the context of lytic therapy. Importantly, post-PCI microvascular integrity is a predictor of 3-month left ventricular systolic function in STEMI patients initially treated with thrombolysis.

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:-Ioannis Anastasiou reports non-financial support from the Hellenic Cardiovascular Research Society.-Alexandros Patrianakos reports non-financial support from the Hellenic Cardiovascular Research Society.-Michail Vernardos reports non-financial support from the Hellenic Cardiovascular Research Society.-Emmanouil Foukarakis reports non-financial support from the Hellenic Cardiovascular Research Society.-Michail Pitarokoilis has nothing to disclose.-Stylianos Petousis reports grants from the Hellenic Cardiovascular Research Society.-Evangelos Zacharis reports non-financial support from the Hellenic Cardiovascular Research Society, and personal fees from Sanofi and Amgen.-Maria Marketou has nothing to disclose.-Emmanouil Skalidis reports grants from the Hellenic Cardiovascular Research Society, and personal fees from AstraZeneca, Medtronic, Boehringer-Ingelheim and Pfizer.-George Kochiadakis reports non-financial support from the Hellenic Cardiovascular Research Society, personal fees from AstraZeneca and Sanofi, and grants from Innovis, 10.13039/501100011725Servier and 10.13039/100001316Abbott.-Fragkiskos Parthenakis reports grants from the Hellenic Cardiovascular Research Society.-Panos Vardas reports personal fees from Menarini International, Dean Medicus, Servier, the European Society of Cardiology and Hygeia Hospitals Group.-Michalis Hamilos reports grants and personal fees from the Hellenic Cardiovascular Research Society, and personal fees from AstraZeneca and Sanofi.